This article presents the development and evaluation of two novel albumin-binding CCK2R-targeted radiopharmaceuticals, DOTA-INER-PP-F11N-1 and DOTA-INER-PP-F11N-2, designed to address the key limitations of existing CCK2R-targeted agents such as 177Lu-DOTA-PP-F11N, particularly in terms of in vivo stability, tumor selectivity, and renal toxicity. The gene discussed is CCKBR; the disease is neoplasm.